Endothelin-1 Receptor Blockade in Resistant Hypertension (ENDOTHELIN-2)
VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
Sponsor: University Hospital, Rouen
This PHASE2 trial investigates Resistant Hypertension and is currently actively recruiting participants. University Hospital, Rouen leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Unknown → Recruiting
-
Sep 2024 — Feb 2026 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Jun 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Rouen
For direct contact, visit the study record on ClinicalTrials.gov .